Researchers at North Carolina State University are exploring an innovative method for vaccine delivery using dental floss. This approach aims to enhance the administration of vaccines for illnesses such as influenza and COVID-19. In recent animal trials, the researchers applied vaccine material to unwaxed dental floss and used it to floss the teeth of lab mice. The results indicated that this method stimulated a significantly stronger antibody response in mucosal surfaces compared to traditional vaccination methods like nasal sprays.
Harvinder Singh Gill, a corresponding author of the study, explained that mucosal surfaces, which include the linings of the nose and lungs, are critical entry points for pathogens. By delivering vaccines through these surfaces, the body can produce antibodies both in the bloodstream and at the mucosal level, offering a more robust defense against infections.
The junctional epithelium, a tissue located between the teeth and gums, is particularly permeable and allows for effective vaccine absorption. This characteristic presents a unique opportunity for introducing vaccines in a manner that enhances immune response. The dental floss method has shown promise in preliminary studies, suggesting potential applicability for various vaccine types, including those based on mRNA technology.
While this method is still in the experimental phase and not yet ready for human use, researchers are considering practical applications, such as the use of floss picks to facilitate administration. Initial tests indicate that a significant portion of the vaccine could be effectively delivered into the gum pocket.
As this research progresses, the team is optimistic about the implications for future vaccine delivery, particularly as an alternative for those who may be hesitant about traditional needle-based vaccinations. Clinical trials are anticipated in the future, contingent on the findings from ongoing studies.